Effect of beta blockers in acute and chronic coronary syndromes without reduced ejection fraction: a landmark analysis from the REBOOT trial

In invasively treated MI patients with LVEF >40%, beta-blockers did not reduce adverse outcomes in either the ACS or CCS phases. These findings challenge their routine use in this population and support reconsidering current guidelines. Long-term beta-blocker users after MI may be candidates for deprescription.

Authors

Institutions

Publication Details

Journal
European Heart Journal - Cardiovascular Pharmacotherapy
Published
2026-01-20
DOI
https://doi.org/10.1093/ehjcvp/pvag002
Primary Topic
Acute Myocardial Infarction Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effect of beta blockers in acute and chronic coronary syndromes without reduced ejection fraction: a landmark analysis from the REBOOT trial

Rocío Barquero, Noemí Escalera, Sergio García‐Blas, Giulietta Grigis et al.
European Heart Journal - Cardiovascular Pharmacotherapy
Acute Myocardial Infarction Research
article

Effect of beta blockers in acute and chronic coronary syndromes without reduced ejection fraction: a landmark analysis from the REBOOT trial

Rocío Barquero, Noemí Escalera, Sergio García‐Blas, Giulietta Grigis, A Castro Torres, Francisco Marín, Alfredo Vetrano, Jaume Agüero, Alberto Domínguez-Rodríguez, Roberto Adriano Latini, Ruth Owen, Borja Ibáñez, Manuel Anguita, Stuart Pocock, Pablo Pastor, Carlos Nicolás Pérez-García, José A Barrabés, Pedro L Sánchez, Alessandro Sionis, Lidia Staszewsky, Andrea Kallmeyer
article en

Abstract

In invasively treated MI patients with LVEF >40%, beta-blockers did not reduce adverse outcomes in either the ACS or CCS phases. These findings challenge their routine use in this population and support reconsidering current guidelines. Long-term beta-blocker users after MI may be candidates for deprescription.

European Heart Journal - Cardiovascular PharmacotherapyVol. 12(2)
University of London (GB), Universidad de La Laguna (ES), Mario Negri Institute for Pharmacological Research (IT), Hospital Universitario de Canarias (ES), Hospital de Sant Pau (ES), Hospital Universitari Arnau de Vilanova (ES), University Hospital Complex Of Vigo (ES), Hospital Universitari i Politècnic La Fe (ES), London School of Hygiene & Tropical Medicine (GB), Hospital Universitario Virgen Macarena (ES), Instituto Maimónides de Investigación Biomédica de Córdoba (ES), Centro de Investigación en Red en Enfermedades Cardiovasculares (ES), Azienda Ospedaliera Bolognini Seriate (IT), Mount Sinai Hospital (US), Hospital Txagorritxu (ES), Centro de Investigación Biomédica en Red (ES), Health Research Institute of the Balearic Islands (ES), Vall d'Hebron Hospital Universitari (ES), Hospital Universitario Fundación Jiménez Díaz (ES), Spanish National Centre for Cardiovascular Research (ES), Instituto de Investigación Biomédica de Lleida (ES), Instituto de Investigación Biomédica de Salamanca (ES), Guglielmo da Saliceto Hospital (IT), Instituto Murciano de Investigación Biosanitaria (ES), Ospedale Sant'Anna (IT), Hospital Universitario Virgen de la Arrixaca (ES), Fundación Canaria de Investigación Sanitaria (ES), Hospital Universitario Son Espases (ES), Instituto Canario de Investigaciones Agrarias (ES), Hospital Universitario de León (ES), Universitat de les Illes Balears (ES), Universidad Autónoma de Madrid (ES)
Good health and well-being
Openalex Percentile: Top 82%
Acute Myocardial Infarction Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.